AI Cancer Vaccine Shows Surging 75% Response in Phase 2 Trial
Evaxion reported a 75% objective response rate in a 16-patient Phase 2 study of EVX-01 plus pembrolizumab in first-line...
Jon Napitupulu
FDA Approves Junshi’s New Phase 2/3 NSCLC Clinical Study
Junshi Biosciences has received FDA IND clearance to initiate an international, open-label, randomized phase 2/3 study testing its PD-1/VEGF...
NEJM Publishes Successful China Phase 3 Lupus Drug Data
Telitacicept produced a 67.1% modified SRI-4 response at week 52 versus 32.7% on placebo (P<0.001) in a 335‑patient Phase...
Surging DNA Cancer Vaccine Market: Trials & FDA Insight
First approval for a DNA cancer vaccine could land by 2030, with more than 20 candidates now in clinical...
ANI Pharma to Present New Day Clinical Trial Data at AAO 2025
No new efficacy or safety figures were disclosed in today’s announcement, but ANI Pharmaceuticals will showcase the already reported...
Anteris Gets First EU Clearance for DuraVR Pivotal Trial
The PARADIGM pivotal trial will randomize approximately 1,000 “all-comer” patients with severe calcific aortic stenosis 1:1 to the DurAVR...
Artelo to Present Expanded Clinical Data at Cannabinoid Summit
Patients in Artelo’s CAReS Phase 2 trial of ART27.13, a once-daily dual cannabinoid agonist for cancer-related anorexia, gained an...
MMI’s New Robotic Study Enrolls Its First Patient in U.S.
Up to 455 patients across two cohorts will be enrolled in a prospective, multi-center U.S. study evaluating the Symani...
Aprea Sets Phase 2 Dose for ATRN-119 Combination Therapy
Aprea set the monotherapy recommended Phase 2 dose for ATRN-119, its oral ATR inhibitor, at 1,100 mg once daily...
First Patient Enrolled for Prostate Cancer Trial in Japan
Curium’s global Phase 3 ECLIPSE trial of 177Lu-PSMA-I&T met its primary endpoint with statistically significant, clinically meaningful benefit in...